|
🐜
|
Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection.
11 auth.
A. Lopes,
P. Kellam,
Abhishek Das,
C. Dunn,
A. Kwan,
J. Turner,
...
D. Peppa,
Richard J. Gilson,
A. Gehring,
A. Bertoletti,
M. Maini
|
7 |
2008 |
7
🐜
|
|
🦁
|
Newborn screening for severe combined immunodeficiency and T-cell lymphopenia in California: results of the first 2 years.
15 auth.
A. Kwan,
Joseph A. Church,
M. Cowan,
R. Agarwal,
N. Kapoor,
Donald B. Kohn,
David B. Lewis,
S. McGhee,
Theodore B. Moore,
E. R. Stiehm,
...
M. Porteus,
C. Aznar,
R. Currier,
F. Lorey,
J. Puck
|
7 |
2013 |
7
🦁
|
|
🐜
|
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study
21 auth.
L. Budde,
S. Assouline,
L. Sehn,
S. Schuster,
S. Yoon,
D. Yoon,
M. Matasar,
F. Bosch,
W. Kim,
L. Nastoupil,
...
I. Flinn,
M. Shadman,
C. Diefenbach,
C. O'Hear,
Huang Huang,
A. Kwan,
Chi-Chung Li,
E. Piccione,
M. Wei,
S. Yin,
N. Bartlett
|
7 |
2021 |
7
🐜
|
|
🐜
|
Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines.
18 auth.
S. Schuster,
N. Bartlett,
S. Assouline,
S. Yoon,
F. Bosch,
L. Sehn,
C. Cheah,
M. Shadman,
G. Gregory,
M. Ku,
...
M. Wei,
S. Yin,
A. Kwan,
K. Yousefi,
G. Hernandez,
Chi-Chung Li,
C. O'Hear,
L. Budde
|
7 |
2019 |
7
🐜
|
|
🐜
|
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.
20 auth.
L. Budde,
L. Sehn,
M. Matasar,
S. Schuster,
S. Assouline,
P. Giri,
J. Kuruvilla,
M. Canales,
S. Dietrich,
K. Fay,
...
M. Ku,
L. Nastoupil,
C. Cheah,
M. Wei,
S. Yin,
Chi-Chung Li,
Huang Huang,
A. Kwan,
E. Penuel,
N. Bartlett
|
7 |
2022 |
7
🐜
|
|
🦁
|
History and current status of newborn screening for severe combined immunodeficiency.
A. Kwan,
J. Puck
|
6 |
2015 |
6
🦁
|
|
🐜
|
Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC).
10 auth.
S. Stein,
M. Pishvaian,
Michael S. Lee,
Kyung-Hun Lee,
Sairy G. Hernandez,
A. Kwan,
...
Bo Liu,
W. Grossman,
K. Iizuka,
B. Ryoo
|
6 |
2018 |
6
🐜
|
|
🐜
|
Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B.
15 auth.
D. Punwani,
Yong Zhang,
Jason S. L. Yu,
M. Cowan,
Sadhna Rana,
A. Kwan,
Aashish N. Adhikari,
C. Lizama,
Bryce A. Mendelsohn,
Shawn P. Fahl,
...
Ajithavalli Chellappan,
Rajgopal Srinivasan,
S. Brenner,
D. Wiest,
J. Puck
|
6 |
2016 |
6
🐜
|
|
🐜
|
Newborn Screening for SCID Identifies Patients with Ataxia Telangiectasia
11 auth.
J. Mallott,
A. Kwan,
J. Church,
D. González-Espinosa,
F. Lorey,
Ling Fung Paul Tang,
...
Uma Sunderam,
Sadhna Rana,
Rajgopal Srinivasan,
S. Brenner,
J. Puck
|
6 |
2012 |
6
🐜
|
|
🐜
|
Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer
18 auth.
Z. Khan,
F. Di Nucci,
A. Kwan,
C. Hammer,
S. Mariathasan,
V. Rouilly,
J. Carroll,
M. Fontes,
Sergio Ley Acosta,
E. Guardino,
...
Haiyin Chen-Harris,
T. Bhangale,
I. Mellman,
J. Rosenberg,
T. Powles,
J. Hunkapiller,
G. S. Chandler,
Matthew L. Albert
|
6 |
2019 |
6
🐜
|
